Carna Biosciences, Inc. (TYO:4572)

Market Cap	8.00B +38.3%
Revenue (ttm)	579.00M -9.0%
Net Income	-2.17B
EPS	-113.60
Shares Out	19.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,100
Average Volume	177,615
Open	435.00
Previous Close	432.00
Day's Range	416.00 - 435.00
52-Week Range	200.00 - 512.00
Beta	0.22
RSI	60.64
Earnings Date	May 8, 2026

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 61
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4572

Financial Performance

In 2025, Carna Biosciences's revenue was 579.00 million, a decrease of -8.96% compared to the previous year's 636.00 million. Losses were -2.17 billion, -0.32% less than in 2024.